Sarepta Therapeutics (SRPT) remains unprofitable, but the company has reduced its losses by 27.2% per year over the last five years and is forecast to grow earnings at an impressive 48.63% per year.

The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.

Sarepta stock crashed Tuesday after the biotech company said two of its muscular dystrophy drugs failed confirmatory tests.

Sarepta Therapeutics (SRPT) has caught the attention of investors after shares rose nearly 2% in recent trading. The move comes as the biotech sector shows mixed results and puts a spotlight on ...

Shares of Sarepta Therapeutics ($SRPT) plunged after the company reported disappointing results from a key trial of its Duchenne muscular ...

Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...

The firm's stock tumbled on the news, dropping from $24.45 per share at market close Monday to $15.24 per share when the market opened Tuesday.

Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid ...

Sarepta Pharmaceuticals Inc (NASDAQ: SRPT) stock is plummeting down, down 31.4% at $16.77 at last glance. Though the biotech ...

Sarepta Therapeutics shares plunged 37% after two Duchenne muscular dystrophy drugs failed a key trial, raising regulatory ...

Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting ...

Still, CEO Doug Ingram claimed removing the two drugs, Vyondys 53 and Amondys 45, from market would make “little sense” and ...